- Home
- CRON vs GHRS Comparison
CRON vs GHRS Comparison
Compare CRON & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- GHRS
- Stock Information
- Founded
- CRON N/A
- GHRS 2018
- Country
- CRON Canada
- GHRS Ireland
- Employees
- CRON N/A
- GHRS N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- GHRS Health Care
- Exchange
- CRON Nasdaq
- GHRS Nasdaq
- Market Cap
- CRON 809.4M
- GHRS 774.1M
- IPO Year
- CRON N/A
- GHRS 2021
- Fundamental
- Price
- CRON $2.49
- GHRS $14.00
- Analyst Decision
- CRON
- GHRS Strong Buy
- Analyst Count
- CRON 0
- GHRS 9
- Target Price
- CRON N/A
- GHRS $29.33
- AVG Volume (30 Days)
- CRON 2.0M
- GHRS 310.6K
- Earning Date
- CRON 11-06-2025
- GHRS 11-13-2025
- Dividend Yield
- CRON N/A
- GHRS N/A
- EPS Growth
- CRON N/A
- GHRS N/A
- EPS
- CRON 0.05
- GHRS N/A
- Revenue
- CRON $130,282,000.00
- GHRS N/A
- Revenue This Year
- CRON $19.67
- GHRS N/A
- Revenue Next Year
- CRON $30.56
- GHRS N/A
- P/E Ratio
- CRON $51.19
- GHRS N/A
- Revenue Growth
- CRON 28.01
- GHRS N/A
- 52 Week Low
- CRON $1.60
- GHRS $6.72
- 52 Week High
- CRON $3.16
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- CRON 47.74
- GHRS 54.05
- Support Level
- CRON $2.44
- GHRS $12.40
- Resistance Level
- CRON $2.57
- GHRS $14.54
- Average True Range (ATR)
- CRON 0.10
- GHRS 0.86
- MACD
- CRON -0.02
- GHRS 0.08
- Stochastic Oscillator
- CRON 19.48
- GHRS 65.96
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.